Business Cocktail

May 17, 2018

Zymeworks Daiichi I-O deal could potentially be worth USD 485 million Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains. The pair is now entering into a new license agreement with a potential deal worth of around USD 484.7 million....

May 08, 2018

Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&D program Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Genentech, Berger was involved in the approval of several drugs including the PD-L1 checkpoint inhibitor Tecentriq. Berger w...

May 03, 2018

Horizon Discovery declines Abcam’s USD 367 million takeover bid Horizon Discovery has recently rejected a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique and has issued a strong rejection to the offer of Abcam. Horizon’s board believes that the bid unde...

Mar 28, 2018

Novo Holdings optimistic about investments in life sciences Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe. They are optimistic about the investment in life-science companies with their past experience. NMD gets USD 47 million...

Mar 15, 2018

M&A activity of Sanofi and Bioverative for rare blood diseases Sanofi has strengthened its position in hematology & speciality medicine by acquiring Bioverativ, Biogen hemophilia & blood disorders-focused company for USD 105 per share on March 8, 2018. This will increase Sanofi’s hemophilia portfolio for...

Feb 22, 2018

Ionis pharmaceuticals recently licensed-out its antisense drug to AstraZeneca in deal total worth up to USD 330 million Ionis Pharmaceuticals has recently licensed-out an antisense drug to AstraZeneca, bagging a payment of USD 30 million as an upfront licensing fee. AstraZeneca will now be taking care of the develo...

Jan 12, 2018

Adapsyn signed a USD 162 million deal with Pfizer for microbe-mining project Adapsyn has recently signed a deal with Pfizer for the microbe-mining with the help of advance platform developed by the Canadian company adapsyn. The technique offers a quick filter for promising candidates with better efficacy. Due to the...

Dec 07, 2017

AbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a pha...

Nov 10, 2017

Takeda and Portal Instruments partner to bring about needle-free form of drug delivery Takeda Pharmaceutical and Portal Instruments have partnered with a deal worth $100 million to develop a needle-free drug delivery device and increase patient compliance rates for biologic medicines manufactured by the former compa...

Sep 20, 2017

Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion In July last year Chinese company Shanghai Fosun Pharmaceutical announced to acquire 74% per cent stake in Gland Pharma (Hyderabad-based Company) for not more than USD 1.09 billion. Initially the deal was set...